References
Roduit C, Frei R, Depner M, Schaub B, Loss G, et al; the PASTURE study group. J Allergy Clin Immunol. 2014. doi:10.1016/j.jaci.2013.12.1044.
Yaghmaie P, Koudelka CW, Simpson EL. Psychiatric comorbidity in pediatric eczema. J Invest Dermatol. 2011;131(Supplement 1):S41 (Abstract #246).
Deckert S, Kopkow C, Schmitt J. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy. 2014;69(1):37–45.
Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56–61.
Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014;70(2):e37–8. doi:10.1016/j.jaad.2013.10.054.
Stein L, Kircik L, Fowler J, Tan J, Draelos Z, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316–23.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503–10.
Papp K, Griffiths C, Leonardi C, Reich K, Kircik L, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1). Poster 8359. AAD meeting, Denver (2014).
Papp KA, Menter A, Strober B, Langley RG, Buonanno M, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77.
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9.
Debbaneh MG, Levin E, Sanchez Rodriguez R, Leon A, Koo J, Rosenblum MD. Plaque-based sub-blistering dosimetry: Reaching PASI-75 after two treatments with 308-nm excimer laser in a generalized psoriasis patient. J Dermatol Treat. 2014 (Epub ahead of print).
Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600–8.
Elewski B, Zane L, Rich P, Aly R, Soto RG. Pivotal phase III safety and efficacy results of tavaborole (AN2690), a novel boron-based molecule for the topical treatment of toenail onychomycosis. Poster 8730. AAD meeting, Denver (2014).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fraser, K. 72nd Annual Meeting of the American Academy of Dermatology. Am J Clin Dermatol 15, 143–145 (2014). https://doi.org/10.1007/s40257-014-0073-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-014-0073-9